PMID- 26932854
OWN - NLM
STAT- MEDLINE
DCOM- 20170317
LR  - 20181202
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 96
IP  - 8
DP  - 2016 Mar 1
TI  - [Clinical and biological characteristics multiple myeloma with 1q21 
      amplification].
PG  - 615-9
LID - 10.3760/cma.j.issn.0376-2491.2016.08.007 [doi]
AB  - OBJECTIVE: To study the clinical features of multiple myeloma (MM) patients with 
      1q21 amplification and the detection and biological characteristics of 1q21 copy 
      number variation among different stages of plasma cell dyscrasias. METHODS: We 
      analyzed the amplification and copy number variation of 1q21 in a cohort of 397 
      MM patients (290 newly diagnosed patients and 107 relapsed/refractory patients) 
      in Institute of Hematology and Blood Diseases Hospital in the period between 
      January 2009 and December 2012, using fluorescence in situ hybridization (FISH). 
      We compared the incidence and biological characteristics of 1q21 gains among 
      different stages of MM. RESULTS: Among the newly diagnosed MM patients, the cases 
      without 1q21 gains (148 cases) had difference prevalence of q13 deletion (38.3% 
      (56/146) vs 57.7% (82/142), P=0.001), t(4; 14) translocation (17.4% (25/144) vs 
      30.7% (42/137), P=0.009), and high-risk cytogenetic abnormalities (28.3% (39/138) 
      vs 41.9% (57/136), P=0.018), and International Staging System (ISS) stage 
      (P=0.010) compared to those with 1q21 gains (142 cases); however, there were no 
      significant differences in age(P=0.448), Durie-Salmon clinical stage (P=0.352) 
      and beta2-microglobulin level (P=0.414). In the newly diagnosed patients, the 
      incidence of this 1q21 aberration with the percentages of plasma cells involved 
      being >/=10%, >/=20%, and >/=30% was 52.4% (152/290), 49.0% (142/290), and 46.2% 
      (134/290), respectively, lower than that in the relapsed/refractory patients 
      (71.0% (76/107), P=0.001; 68.2% (73/107), P=0.001; 63.6% (68/107), P=0.002). 
      Differences were found between the newly diagnosed MM patients and the 
      relapsed/refractory ones in terms of the incidence of 1q21 copy number gains 
      being 2 (52.2% (145/278) vs 33.3% (34/102), P=0.001), but not in the incidence of 
      1q21 copy number gains being 3, 4, and >5 (all P>0.05). CONCLUSIONS: 
      Amplification of chromosome 1q21 is a common genetic abnormality in MM patients. 
      The copy number varies in patients carrying 1q21 gains, mainly with two or more 
      copies of 1q21. It may therefore be recommended to include testing for 1q21 gains 
      in routine genetic testing of MM patients.
FAU - Zhong, Shizhen
AU  - Zhong S
AD  - State Key Laboratory of Experimental Hematology, Department of Lymphoma, 
      Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Tianjin 300020, China.
FAU - Li, Chengwen
AU  - Li C
FAU - Yi, Shihua
AU  - Yi S
FAU - Qiu, Lugui
AU  - Qiu L
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
SB  - IM
MH  - Chromosome Aberrations
MH  - *Chromosomes, Human, Pair 1
MH  - *DNA Copy Number Variations
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Multiple Myeloma
MH  - Paraproteinemias
EDAT- 2016/03/05 06:00
MHDA- 2017/03/18 06:00
CRDT- 2016/03/03 06:00
PHST- 2016/03/03 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2017/03/18 06:00 [medline]
AID - 10.3760/cma.j.issn.0376-2491.2016.08.007 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2016 Mar 1;96(8):615-9. doi: 
      10.3760/cma.j.issn.0376-2491.2016.08.007.